Tvardi Therapeutics, Inc. (TVRD) Investor Relations Documents

Tvardi Therapeutics, Inc. (TVRD) investor relations documents from the company's IR site: 2 presentations, 16 press releases; latest deck 2026-08-19. Read in-app with summaries. First-party data.

Presentation: KOL Webinar on Potential of TTI-109 in UC: TTI-109, an oral STAT3 inhibitor, shows promise in Ulcerative Colitis by reducing key immune cells implicated in disease pathology.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19PresentationPresentation: KOL Webinar on Potential of TTI-109 in UC
2026-08-14Press releasePDF Version
2026-08-14Press releaseTvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
2026-08-12Press releasePDF Version
2026-08-12Press releaseTvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving
2026-08-07PresentationCorporate Presentation
2026-07-30Press releasePDF Version
2026-07-30Press releaseTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
2026-07-07Press releaseTvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence o
2026-05-21Press releaseTvardi Therapeutics to Participate in Upcoming Investor Events
2026-05-08Press releaseTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-04-02Press releaseTvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-03-31Press releaseTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-02-12Press releaseTvardi Therapeutics to Participate in Upcoming Investor Conferences
2026-01-08Press releaseTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-08Press releaseTvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
Press releaseTvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
Press releaseFDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

TVRD overview · TVRD earnings · TVRD financials · TVRD KPIs · TVRD ownership · TVRD peers · TVRD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.